SOURCE: The Bedford Report

The Bedford Report

December 16, 2011 08:16 ET

Recent FDA Approvals for Antares Pharma and Boston Scientific Have Done Little to Boost Shares

The Bedford Report Provides Equity Research on Antares Pharma & Boston Scientific

NEW YORK, NY--(Marketwire - Dec 16, 2011) - Unlike most of the so-called "recession proof" healthcare sector, the medical equipment and supplies industry has underperformed the S&P 500 by a rather large margin this year. Down more than 18 percent over the last year, medical supply makers are seeing their margins squeezed as President Obama's healthcare reform and increased regulation is threatening the industry's pricing environment.The Bedford Report examines investing opportunities in the Medical Equipment & Supplies industry and provides equity research on Antares Pharma, Inc. (NYSE Amex: AIS) and Boston Scientific Corporation (NYSE: BSX). Access to the full company reports can be found at:

Boston Scientific Corporation develops, manufactures, and markets medical devices used in various interventional medical specialties worldwide. Earlier this month the company announced U.S. Food and Drug Administration (FDA) approval of the "Infinion16 Percutaneous Lead for its Precision Plus Spinal Cord Stimulator (SCS) System," the first rechargeable SCS device for chronic pain management. According to Boston Scientific, the Precision Plus Spinal Cord Stimulator System, powered by SmoothWave Technology, uses pulses of electricity delivered directly along nerve fibers through the spinal cord to mask pain signals to the brain.

The Bedford Report releases stock reports on the Medical Equipment & Supplies Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at and get exclusive access to our numerous analyst reports and industry newsletters.

Antares Pharma, Inc., a pharmaceutical company, focuses on self-injection pharmaceutical products and technologies, and topical gel-based products. Last week the FDA approved a topical gel from Antares for the treatment of overactive bladder. Antares said overactive bladders affect more than 33 million Americans. The condition is characterized by a sudden, uncomfortable need to urinate and may include incontinence.

Antares Pharma says it will launch the product with Watson Pharmaceuticals Inc., which will sell it in the United States and Canada.

The Bedford Report provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Bedford Report has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at:

Contact Information